Defense is favored atleast right now #ABBVAscending triangle breakout will be bullish for ABBV. Things going for ABBV have been lot of insider buying. If it breaks out, will add more
ABBV trade ideas
ABBV Looking to break through Ichi CloudABBV has broken and retested the downward trend line. Looks like it has a good shot to push through cloud resistance.
ABBV Detected possible FDA approval!!!ABBV: abbvie inc
2018-07-24 08:30:26
Detected possible FDA approval
$ABBV - I'm a fan Little extra, but put in both ABCD 61.8% fib corrections just to show definitive correlation for each re-trace. Definitely think that touch of the 50% is needed for an upward swing, but long term I can definitely see a 161% (200% on MA fib) move back up towards $115. Still pretty choppy price action, so my best bet would be to wait until @ or crossing over that $102 (blue WMA) area. Great setup tho
ABBV ABBV is a very high quality stock. It never missed an earnings estimate. Accordingly, my homebrew stock valuation system gives it pretty high scores quality-wise.
"val2_k": 5,
"val2_q": 8,
"qual2_k": 60,
"qual2_q": 51,
"qual3_k": 59
TA wise, It does seem like ABBV is finishing wave 2 and starts making into 3 of (5) of III. Lots of long term potential for this stock.
Though it seems like wave 2 ended at exactly 50% of wave 1, historically, this stocks has shown that wave 2 can retrace upto 76.4% of wave 1. In short, ABBV can find short term low anywhere from 93 to 98 before mooning.
Long term target for wave (5) of III is estimated at $145. A nice 45% potential.
ABBV - when having all your eggs in one basket works outAbbVie's bread winner is Humira - this drug accounts for the majority of their revenue. However, they did forecast that by 2020, revenue from Humira will be $21B - which is about 75% of their 2017 revenue of $28.22B.
Since AbbVie depends so heavily on their flagship, their stock is fairly volatile, giving this play more of a risk. Consider well-hedged positions (like married puts), or at least ITM leap calls.
ABBV continues to fill gap - short-term PT $112NYSE:ABBV PRICE TARGET - $112 in the short-term. We remain long, the fundamental picture looks outstanding!
ABBV gapping upWe have been long ABBV for a while! The stock is gapping up today after the company announced a cash tender offer for up to $7.5B of its common stock at prices between $99 and 114 per share.
ABBV Daily - Short SetupABBV below 200 day sma, triggers short on horizontal support break around 88. Market permitting. Notes on chart. Looks vulnerable here.
"Trade what you see not what you think" Bullish SentimentInterest in this market
ABBV stock- Strong area of support that rallied up to the $125s which clearly shows institutional interest within the 94-98 zone.
1-3 risk to reward whilst still keeping an eye on 85s
Reason for opposing catalyst
Retail Investors had all the there chips in hoping for accelerated approval for the drug Rova-T (Drug) which they forked out just shy of $6 billion for Stemcentrx, (Defeating the purpose of the acquisition)
Risk management
Cut losses quickly
Wait till price action breaches more into the level to buy cheaper
#ABBV #short #stockon the daily chart ABBV has formed a triple top or as I like to say a three kings formation. MACD is leading down. OBV is neutral. stoch rsi is leading down. with a 4 RRR this is a pretty good trade.
weekly
trend is up, however there is a congestion zone on the far right of the chart. macd is crossing down. OBV is rolling over. stoch rsi leading down.
monthly
trend is up and so are all indicators
ABBV Cup and HandleComing into the top trendline with good volume. could see a good break here over 121.
#ABBV #PHARMA LOND IDEA SET UPPrice broke down and bounce in previous resistance at 116. Two possible entries aggressive and conservative.
